Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

← catalyst calendar

NCT04526691

Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

145actual

Sites

Countries

Italy, Japan, Spain +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-09-15

actual

When the study began enrolling

Primary completion

2024-04-14

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-31

estimated

The whole study's end, after follow-up

First posted

2020-08-26

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-15

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced or Metastatic NSCLC

Interventions

Drug: Datopotamab deruxtecan — also filed as Dato-DXd
Drug: KEYTRUDA® — also filed as pembrolizumab
Drug: Carboplatin
Drug: Cisplatin

Primary outcome

what the primary-completion date above is the date OF

Number of Participants with Dose-limiting Toxicities (DLTs) and Treatment-emergent Adverse Events (TEAEs)

measured Baseline up to Cycle 1 (Days 1 to 21) for DLTs and up to 28 days after last dose for TEAEs, up to approximately 30 months post-dose

Publications

PMID 41871716 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed